title: Prasugrel, new platelet inhibitor, subject of formulary debates.
authors.affiliation: Genentech Inc, USA. TMorrow@ManagedCareMag.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D005569:Formularies as Topic; D006801:Humans; D008329:Managed Care Programs; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride